Peptides for Mitochondrial Function Research: MOTS-c, SS-31, Humanin & Protocols

Research comparison of the three mitochondrial-derived peptides — MOTS-c (AMPK activation), SS-31 (cardiolipin binding), and Humanin (cytoprotection/IGF-1) — with dosing protocols, combination rationale, and longevity vs performance applications.

TL;DR

• MOTS-c: Mitochondrial genome-encoded peptide → AMPK activation → insulin sensitivity, metabolic regulation, exercise mimetic
• SS-31 (Elamipretide): Stabilizes cardiolipin in IMM → reduces ROS, improves ATP synthesis
• Humanin: Cytoprotective MDP → anti-apoptotic, IGF-1 pathway modulation, neuroprotection
• All three can be combined safely for comprehensive mitochondrial longevity protocol

Disclaimer: For educational and research purposes only — not medical advice.

The mitochondria — long considered passive "energy factories" — encode their own genome and actively signal to the nucleus and periphery through a growing family of mitochondrial-derived peptides (MDPs). MOTS-c, Humanin, and SS-31 represent three mechanistically distinct approaches to mitochondrial optimization that, together, address the full spectrum of age-related mitochondrial dysfunction.

MOTS-c: The Metabolic Regulator

Origin: Encoded in the 12S rRNA region of mitochondrial DNA; 16 amino acid peptide

Primary mechanism: MOTS-c translocates to the nucleus upon cellular stress and activates AMPK (AMP-activated protein kinase) — the cellular energy sensor. This AMPK activation:

• Improves insulin sensitivity and glucose uptake
• Stimulates fatty acid oxidation
• Activates mitochondrial biogenesis (PGC-1α pathway)
• Reduces visceral fat accumulation
• Mimics some effects of exercise at the metabolic level

Decline with aging: MOTS-c plasma levels decline significantly with age and are lower in type 2 diabetic patients. Exercise increases MOTS-c production.

Research dosing: 5-10mg/week subcutaneous, often split into 2 injections (Monday/Thursday). Some protocols use 5mg before exercise sessions.

SS-31 (Elamipretide): The Structural Stabilizer

Origin: Synthetic tetrapeptide (not endogenous); designed to target inner mitochondrial membrane

Primary mechanism: SS-31 concentrates in the inner mitochondrial membrane (driven by membrane potential) and directly binds cardiolipin — the phospholipid that anchors electron transport chain complexes. This binding:

• Prevents cardiolipin oxidation
• Stabilizes ETC complexes (I, III, IV, V)
• Reduces electron leakage → less ROS production
• Restores ATP synthesis efficiency

Clinical data: Phase 2/3 trials in heart failure (HFpEF) and Barth syndrome (cardiolipin-deficiency disease) show functional improvements — making this the most clinically advanced mitochondrial-targeting peptide.

Research dosing: 0.5-5mg/day subcutaneous. Common protocol: 1-2mg/day.

Humanin: The Cytoprotector

Origin: Encoded in the 16S rRNA region of mitochondrial DNA; 21 amino acid peptide discovered as a neuroprotective factor

Primary mechanism: Humanin is a secreted peptide that acts through two receptor systems:

• FPRL1 (formyl peptide receptor-like 1) — anti-apoptotic signaling
• CNTFR/WSX-1/gp130 complex — cytokine-like neuroprotective signaling

Humanin:

• Protects neurons against amyloid-β toxicity (Alzheimer's research)
• Inhibits BAX-mediated apoptosis
• Modulates IGF-1/GH axis (increases IGF-1 bioavailability)
• Anti-inflammatory in multiple cell types
• Declines rapidly with aging (some of the most dramatic age-related declines of any MDP)

Research dosing: 1-10mg/week subcutaneous. S14G-Humanin (HNG) is a synthetic variant with ~1000x higher potency than native Humanin.

Reconstitution Reference Table

Combined Protocol Design

A mitochondrial peptide longevity stack:

Weekly schedule:

• Monday: MOTS-c 5mg SubQ + SS-31 1mg SubQ
• Wednesday: SS-31 1mg SubQ
• Thursday: MOTS-c 5mg SubQ
• Saturday: SS-31 1mg SubQ + Humanin 2mg SubQ

Supporting compounds:

• NMN 500mg/day (NAD+ support for sirtuin activation)
• Taurine 2g/day (cardiolipin biosynthesis support)
• CoQ10 100-200mg with fat (ETC electron carrier)
• Astaxanthin 4-8mg with fat (mitochondrial membrane antioxidant)

Longevity vs Performance Applications

Frequently Asked Questions

Q: Which mitochondrial peptide should be started first? A: Most researchers begin with SS-31 — it has the most human clinical data and addresses a fundamental mitochondrial dysfunction (cardiolipin oxidation) common to all aging. MOTS-c would be prioritized for those with insulin resistance or metabolic concerns. Humanin for those with neurological/cognitive priorities.

Q: How are these different from standard supplements like CoQ10? A: CoQ10 is an electron carrier within the ETC — it's a small molecule that participates in electron transport but doesn't address structural or regulatory issues. MOTS-c regulates metabolic enzyme expression, SS-31 stabilizes the membrane architecture that ETC complexes depend on, and Humanin signals cytoprotection and anti-apoptosis. These represent fundamentally different and deeper levels of mitochondrial intervention.

Use the Reconstitution Calculator → /calculators/reconstitution

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions